• Explore /
  • Poster
  • / Preliminary activity of veliparib (V) in <em>BRCA2</em>-mutated metastatic castration-resistant prostate cancer (mCRPC).

Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Shalu Pahuja

University of Pittsburgh Cancer Institute, Pittsburgh, PA

Shalu Pahuja , Leonard Joseph Appleman , Chandra Prakash Belani , Alice Chen , Edward Chu , Jan Hendrik Beumer , Shannon Puhalla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT00892736

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 170)

DOI

10.1200/jco.2015.33.7_suppl.170

Abstract #

170

Poster Bd #

H6

Abstract Disclosures

Similar Posters

First Author: Arpit Rao

Poster

2020 Genitourinary Cancers Symposium

Treatment response comparisons between <em>ATM</em> and <em>BRCA2</em> germline carriers for mCRPC.

Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.

First Author: Alexandra Sokolova

First Author: George Somlo

First Author: George Somlo